����ֱ��

Exciting new cancer research is taking place at NCIC Clinical Trials Group (CTG) located on the Queen’s University campus. CTG is a national research program of the Canadian Cancer Society.

Announced today, the new Stand Up To Cancer (SU2C) Canada-CBCF Breast Cancer Dream Team will be focused on four new clinical trials to test three new drugs.

SU2C is a groundbreaking initiative created to accelerate innovative cancer research that will get new therapies to patients quickly and save lives now. The SU2C Canada Breast Cancer Dream Team’s fully integrated translational research model is propelling the group rapidly toward more effective, less toxic therapies for patients with three major breast cancer subtypes.

“The NCIC CTG is very pleased to be running the clinical trials of the promising innovative new agents arising from the . These will hopefully turn into new options for patients with breast cancer,” says Janet Dancey, director NCIC CTG.

 “These four clinical trials test three new drugs all of which look promising in the laboratory,” says Lesley Seymour, director IND Program and Compliance, NCIC CTG.    “Cutting edge translational work – looking to better understand how these new drugs work – will be conducted in the laboratories of the Dream Team.”

The announcement takes place Wednesday, September 30 in the MaRS Discovery District.

The NCIC CTG is the only Canadian cooperative cancer trials group conducting the entire range of cancer trials from early phase studies to large international randomized controlled trials across all cancer types. Its primary mission is to assess the effectiveness of interventions to prevent the development of cancer or improve the care of those patients who do develop cancer. It is a national research program of the Canadian Cancer Society.